FDA Approved: ARCALYST — Original Application (Kiniksa Pharmaceuticals (UK), Ltd.)

View source ↗

Summary

FDA approved ARCALYST (rilonacept) from its original Biologics License Application for the treatment of cryopyrin-associated periodic syndromes (CAPS), includin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cryopyrin-associated Periodic Syndromes
• Familial Cold Autoinflammatory Syndrome
• Muckle-wells Syndrome
• Neonatal-onset Multisystem Inflammatory Disease

Drugs mentioned

• Arcalyst (rilonacept)

Snippet

ORIG AP for ARCALYST (RILONACEPT)